Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Pliant Therapeutics, Inc.
M.D. Anderson Cancer Center
Novartis
Hangzhou Hanx Biopharmaceuticals, Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Genentech, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
University Health Network, Toronto
OncoC4, Inc.
Pfizer
Genmab
USWM, LLC (dba US WorldMeds)
Alliance for Clinical Trials in Oncology
Pfizer
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Aulos Bioscience, Inc.
Ipsen
AstraZeneca
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Bristol-Myers Squibb
National Cancer Institute (NCI)
Pfizer
Brigham and Women's Hospital
Hoffmann-La Roche
Wake Forest University Health Sciences
AstraZeneca
Centre Oscar Lambret
Fondazione del Piemonte per l'Oncologia
Dana-Farber Cancer Institute
Mayo Clinic
BioNTech SE
Ohio State University
Mayo Clinic